Chargement en cours...
Cost effectiveness of pharmacogenetic testing for UGT1A1 before irinotecan administration for metastatic colorectal cancer
PURPOSE: To examine the cost effectiveness of using a pharmacogenetic test for UGT1A1*28 variant homozygosity before administering irinotecan in metastatic colorectal cancer patients. Patients and Methods: Decision-analytic model from Medicare payer perspective followed hypothetical patients treated...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2853177/ https://ncbi.nlm.nih.gov/pubmed/19517472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24428 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|